Corrigendum through General Announcement regarding disclosure of Ultimate Beneficial Owners (UBO''s), Pre - Preferential Shareholding of Proposed Allotees and bifurcation and bried description ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals has issued a corrigendum to its earlier EGM disclosures (held on October 22, 2025) concerning a preferential issue of Equity Shares and Warrants. The update provides a consolidated list of the 18 proposed allottees along with their Ultimate Beneficial Owners (UBOs), including notable names such as Alchemy Capital Management (linked to the Estate of Late Rakesh Jhunjhunwala), R R Family Trust, NAV Capital, and several HNIs and HUFs. It also discloses pre-preferential shareholding of existing allottees (totaling ~15.98 lakh shares) and a detailed use-of-funds plan for the ~₹153.25 crore raise: Brand Marketing & Distribution (35%, ₹49–53 Cr), Working Capital (35%, ₹53–59 Cr), Strategic & Statutory Reserves (15%, ₹22–25 Cr), CAPEX (5%, ₹6–7 Cr), R&D (5%, ₹7–8 Cr), and Contingency (5%, ₹7–8 Cr). The company clarifies this corrigendum does not change the terms, conditions, or rights of the proposed allotment.
This is a procedural compliance update, not a new event – it reinforces transparency around the ~₹153 Cr preferential raise aimed at funding the company's expansion into Pet Care, Human Wellness, and Pharma Generics divisions, including international markets (Sri Lanka, UAE, Philippines, African nations). Stock price reaction is likely neutral unless clarity on issue price and timeline of allotment emerges.